In vitro comparison of CD20xCD3 biosimilar antibodies against diffuse large B cell lymphoma (DLBCL) cell lines with different levels of expression of CD20
Year: 2025
Type: article
Abstract: Although CD20xCD3 bispecific antibodies (BsAbs) have demonstrated transformational activity in DLBCL, some patients fail to respond and others relapse. To begin to explore possible limitations we compared the in vitro activity of four CD20xCD3 biosimilar BsAbs against four DLBCL cell lines with CD20 expression ranging over a hundred-fold. All four biosimilar BsAbs demonstrated superior in vitro activity to rituximab, with biosimilar glofitamab consistently being the most potent. Moreover, biosimilar glofitamab and odronextamab retained significant activity in the presence of low-level CD20 expression. Finally, one DLBCL cell line exhibited intrinsic resistance to all four CD20xCD3 BsAbs despite inducing marked T-cell and NK cell activation.
Source: Figshare
Authors: Joshua S Bray (20764099), Gethin R. Thomas (17388142), Victoria M Smith (8194557), Adam Wright (16422207), Sandrine Jayne (20340567), Martin J. S. Dyer (7583432), Harriet S. Walter (15024867)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7025274444
FWCI:
Cites:
Cited by:
Related to: